FDA Re-Opens Comment Period On Follow-On Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is re-opening the comment period on follow-on biologics until March 16
You may also be interested in...
FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting
The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.